KDR and atopic eczema: The spectrum of CAEs includes both class-specific toxicities, such as HFSR in VEGFR inhibitors, and broader cutaneous manifestations like xerosis, eczematous dermatitis, pruritus, nail disorders, and pigmentary changes.